Coya Therapeutics
COYA | NASDAQ
$3.00
-$0.13 (-4.15%)
At close: Nov 16, 2026, 4:00 PM ET
$2.96
-$0.04 (-1.33%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Coya Therapeutics Company Profile
Company profile explainedCompany Profile
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
Key Executives
| Name | Position |
|---|---|
| Arun Swaminathan | Chief Executive Officer & Director |
| David S. Snyder | Chief Financial Officer & Chief Operating Officer |
| Aaron Thome | Head of Neuroinflammation Platform |
| Fred Grossman FAPA | President & Chief Medical Officer |
| Karen King | Senior Vice President of Program Management & Clinical Operations |
| Michelle Frazier | Senior Vice President of Regulatory |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 14, 2026 | 8-K | Current Report |
| Oct 05, 2026 | 8-K | Current Report |
| Sep 15, 2026 | 8-K | Current Report |
| Aug 11, 2026 | 10-Q | Quarterly Report |
| Aug 11, 2026 | 8-K | Current Report |
| Aug 07, 2026 | 8-K/A | [Amend] Current Report |
| Jul 27, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jun 25, 2026 | 8-K | Current Report |
| May 13, 2026 | ARS | Filing |
| May 13, 2026 | DEFA14A | Filing |
Coya Therapeutics
| Country | United States |
| IPO Date | Dec 29, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Arun Swaminathan |
Contact Details
5850 San Felipe Street Houston,
Texas 77057 United States
Stock Details
| Ticker Symbol | COYA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001835022 |
| CUSIP Number | 22407B108 |
| ISIN Number | US22407B1089 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove COYA